Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses-Reference-Cited by-同舟云学术

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

Published:1999-12 Issue:9-10 Volume:18 Page:899-906
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Treanor John J,Kotloff Karen,Betts Robert F,Belshe Robert,Newman Fran,Iacuzio Dominick,Wittes Janet,Bryant Martin

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. Use of live, attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults;Murphy;Infect. Dis. Clin. Pract.,1993

2. The efficacy of live attenuated cold-adapted trivalent, intranasal influenzavirus vaccine in children;Belshe;N. Engl. J. Med.,1998

3. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease;Edwards;J. Infect. Dis.,1994

4. Development and characterization of cold-adapted viruses for use as live virus vaccines;Maassab;Vaccine,1985

5. Intranasal interferon as prophylaxis against experimentally induced influenza in humans;Treanor;J. Infect. Dis.,1987

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Induction of protective immune responses at respiratory mucosal sites;Human Vaccines & Immunotherapeutics;2024-07-02

2. Mucosal vaccines for viral diseases: Status and prospects;Virology;2024-05

3. Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters;PNAS Nexus;2024-04-30

4. Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines;Expert Review of Vaccines;2024-03-12

5. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet Respiratory Medicine;2023-12